Elironrasib Clinical Trials

2 actively recruiting trials across 2 locations

No change since May 2026

Also known as: RMC-6291

Pipeline

Phase 1/2: 2

Top Sponsors

Revolution Medicines, Inc.2

Indications

Non-small Cell Lung Cancer (NSCLC)2
Lung Cancer2
Cancer2
Metastatic Solid Tumors1
CRC1

Duarte, California1 trial

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

City of Hope

Phase 1/2

Norwich, Connecticut1 trial

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Eastern Connecticut Hematology and Oncology Associates

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.